Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-03-08
2005-03-08
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S219000, C514S220000, C514S825000, C514S863000, C514S886000
Reexamination Certificate
active
06864251
ABSTRACT:
Compounds according to formula I:wherein R1, R2, R3, R4, R5and n are as defined herein, are administered for the treatment of inflammatory disorders mediated by LTB4.
REFERENCES:
patent: 3736315 (1973-05-01), Kórósi et al.
patent: 4322346 (1982-03-01), Kórósi et al.
patent: 4423044 (1983-12-01), Kórósi et al.
patent: 4614740 (1986-09-01), Láng et al.
patent: 4835152 (1989-05-01), Kórósi et al.
patent: 4840948 (1989-06-01), Láng et al.
patent: 5204343 (1993-04-01), Andrási et al.
patent: 5288863 (1994-02-01), Somogyi et al.
patent: 5459137 (1995-10-01), Andrási et al.
patent: 5519019 (1996-05-01), Andrási et al.
patent: 5521174 (1996-05-01), Andrási et al.
patent: 5639751 (1997-06-01), Andrási et al.
patent: 5891871 (1999-04-01), Xia et al.
patent: 6075018 (2000-06-01), Vágó et al.
patent: 6080736 (2000-06-01), Landry
patent: 6638928 (2003-10-01), Harris et al.
patent: 6649607 (2003-11-01), Leventer et al.
patent: 0 492 485 (1992-07-01), None
patent: 178516 (1983-03-01), None
patent: WO 9211262 (1992-07-01), None
patent: WO 0024400 (2000-05-01), None
Don E. Griswold et al., “Technique for Quantification of LTB4-Induced Changes in Peripheral Granulocyte Counts In Vivo in the Rabbit”, Journal of Pharmacological Methods 25, 319-328 (1991).
F. Gatta et al., “Derivatives of 2,3-Benzodiazepine (*)”, II Farmaco—Ed. Sc.—vol. 40—fasc. 12, pp. 942-955.
R. Sladká et al., “A Placebo-controlled Clinical Trial with Tofizopam * in the Treatment of Anxiety Neurosis” Divisions of Psychiatry, District Institutes of National Health, Prague, 2 and 4; Psychiatric Department and Psychiatric Research Unity, Medical Scholl of Charles University, Prague, Czechoslovakia, pp. 176-180.
Edit J. Horváth et al., “Anxiolytic 2,3-benzodiazepines, their Specific Binding to the Basal Ganglia”, Progress in Neurobiology vol. 60 (2000), pp. 309-342.
E. Tomori et al., “Investigation of the Metabolites of Tofizopam in Man and Animals by Gas-Liquid Chromatography-Mass Spectrometry”, Journal of Chromatography, 241 (1982), pp. 89-99.
Eva Tomori et al., “Investigation of Metabolites of Tofizopam in Man and Animals”, Polish Journal of Pharmacology and Pharmacy, 1984, 36, pp. 423-430., PL ISSN 0301-0214.
Sharon Pellow et al., “The Effects of Tofisopam, a 3,4-Benzodiazepine in Animal Models of Anxiety, Sedation, and Convulsions”, Drug Development Research 7, pp. 61-73 (1986).
A. Bond et al., “A Comparison of the Psychotropic Profiles of Tofisopam and Diazepam”, Fur J Clin Pharmacol (1982) 22, pp. 137-142.
B.S. Tsai et al., “The Leukotriene B4Receptor Agonist/Antagonist Activities of SC-45694 in Human Neutrophils”, The Journal of Pharmacology and Experimental Therapeutics, vol. 268, No. 3, 1994, pp. 1493-1498.
Olu Oyesanmi, M.D. et al., “Hematologic Side Effects of Psychotropics”, Psychosomatics 1999 40, pp. 414-421.
J. Kanto et al., “Tofizopam: A Benzodiazepine Derivative Without Sedative Effect”, International Journal of Clinical Pharmacology, Therapy and Toxicology, vol. 20 No. 7—1982, pp. 309-312.
T. Mennini et al., “Brain Levels of Tofizopam in the Rat and Relationship with Benzodiazepine Receptors”, Naunyn-Schmiedeberg's Arch Pharmacol (1982) 321, pp. 112-115.
K. Maier et al., “The Effect of Tofisopam on Psychic Performance in Persons with More than Average Anxiety: A Controlled Experimental Trial”, Current Therapeutic Research, vol. 35, No. 4, Apr. 1984, pp. 541-548.
Chihiro ITO, Behavioral Pharmacological Study of the Structure-Activity Relationship of Benzodiazepine Derivatives—with Particular Reference to the Activity of 2,3-Benzodiazepine-, (1981) 39(3), pp. 369-384 (Japanese), pp. 1-30 (English Translation).
Milena Rizzo, “Chromatographic Separation of 2, 3-Benzodiazepines”, Journal of Chromatography B, 747 (2000), pp. 203-216.
Miklos Simonyi et al, “Stereoselective Binding of a 2,3-Benzodiazepine to Human Serum Albumin”, Biochemical Pharmacology, vol. 32, No. 12, (1983), pp. 1917-1920.
Giovambattista De Sarro et al., “GYKI 52466 and Related 2,3-Benzodiazepines as Anticonvulsant Agents in DBA/2 Mice”, European Journal of Pharmacology 294 (1995), pp. 411-422.
T. Seppälä, “Tofisopam, A Novel 3,4-Benzodiazepine: Multiple-Dose Effects on Psychomotor Skills and Memory. Comparison with Diazepam and Interactions with Ethanol”, Psychopharmacology 69, (1980), pp. 209-218.
Veijo Saano et al., “Tofizopam Modulates the Affinity of Benzodiazepine Receptors in the Rat Brain”, Pharmacology Biochemistry & Behavior, vol. 17, (1982), pp. 367-369.
Sharon Pellow et al., “The Effects of Tofisopam, a 3,4-Benzodiazepine, in Animal Models of Anxiety, Sedation, and Convulsions”, Drug Development Research 7 (1986), pp. 61-73.
A. Pakkanen et al., “Comparative Study of the Clinical Effects of Tofizopam, Nitrazepam and Placebo as Oral Premedication”, British Journal of Anaesthesics, pp. 1009-1012.
V. Saano et al., “Tofizopam Enhances the Action of Diazepam Against Tremor and Convulsions”, Medical Biology 61: (1983), pp. 49-53.
V. Saano et al., “Tofizopam Selectively Increases the Action of Anticonvulsants”, Medical Biology, 64 (1986), pp. 201-206.
E.-E. Claesson, “Stimulation of Human Myclopoiesis by Leurotriese 8”, Biochemical and Biophysical Research Communications, vol. 131, No. 2 (1985), pp. 579-585.
Julia Visy et al., “The Role of Configuration and Conformation in the Binding of 2,3-Benzodiazepines to Human Serum Albumin”, CHIRALITY 1 (1989), pp. 271-275.
István Tarnawa et al., “Structure-Activity Relationships of 2,3-Benzodiazepine Compounds with Glutamate Antagonistic Action”, Bioorganic & Medical Chemistry Letters, vol. 3, No. 1, (1993), pp. 99-104.
Sergey V. Kalashnikov et al., “Immunomodulating Effects of Tofizopam (Grandaxin®) and Diazepam in Vitro”, Mediators of Inflammation, vol. 11, (2002), pp. 53-59.
Fogassy E. et al., “Studies on the Properties and Structure of Optically Active 1-(3,4-Dimethoxyphenyl)-4-Methyl-5-Ethyl-7,8-Dimethoxy-5H-2,3-Benzodiazepine (Tofizopam)”, Studies in Organic Chemistry, vol. 18, (1984), pp. 229-233.
Mark A. Jagels et al., “Neutrophil Chemotactic Factors Promote Leukocytosis”, The Journal of Immunology, vol. 148, No. 4, Feb. 1992, pp. 1119-1128.
K. Yamaguchi et al., “Tofisopam, A New 2,3-Benzodiazepine. Inhibition of Changes Induced by Stress Loading and Hypothalamic Stimulation”, Can. J. Physiol Pharmaco, vol. 61, (1983), pp. 619-625.
Szegó Judit et al., Selected Passages From the Clinical-Pharmacological and Clinical Trials of Grandaxin®, Acta Pharmaceutica Hungarica vol. 63, (1993), pp. 91-98 (Hungarian). pp. 1-10 (English Translation).
L. Petócz et al., The Main Pharmacological Characteristics of Grandaxin (Tofizopam, Egyt-341), Hungarian Medical Journal, vol. 23, No. 4, (1975), pp. 134-138.
Petócz Luijza, “The Pharmacological Effects of Tofizopam (Grandaxin)®”, Acta Pharmaceutica Hungarica, vol. 63, (1993), pp. 72-82 (Hungarian, pp. 1-4 (English Translation).
Harris Herbert W.
Kucharik Robert F.
Drinker Biddle & Reath LLP
Vela Pharmaceuticals, Inc.
Weddington Kevin E.
LandOfFree
Treatment of LTB4-mediated inflammatory disorders with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of LTB4-mediated inflammatory disorders with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of LTB4-mediated inflammatory disorders with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3368119